Literature DB >> 6372682

Novel carbapenem derivative SF2103A: studies on the mode of beta-lactamase inactivation.

A Yamaguchi, T Hirata, T Sawai.   

Abstract

A novel carbapenem, SF2103A, is a strong inhibitor of various types of beta-lactamase. Equimolar concentrations of SF2103A completely inactivated the cephalosporinases of Proteus vulgaris and Citrobacter freundii and type Ib and type II penicillinases mediated by R plasmids in a progressive manner. The inactivation of the two penicillinases and P. vulgaris cephalosporinase was apparently irreversible; however, when the inactivated enzymes were separated from excess SF2103A by gel filtration, they showed very slow reactivation. The hydrolysis of SF2103A by these three beta-lactamases was below the limit of detection. It is concluded that SF2103A acts as a tight-binding competitive inhibitor for the penicillinases and P. vulgaris cephalosporinase. In contrast, the inactivation of C. freundii cephalosporinase by SF2103A was evidently reversible. The rate constant of reactivation of the enzyme was compatible with the turnover rate of the enzyme in the steady state of SF2103A hydrolysis. Thus, SF2103A simply acts as a poor substrate for C. freundii cephalosporinase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6372682      PMCID: PMC185515          DOI: 10.1128/AAC.25.3.348

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Beta-lactamase inactivation by mechanism-based reagents.

Authors:  J Fisher; J G Belasco; R L Charnas; S Khosla; J R Knowles
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1980-05-16       Impact factor: 6.237

2.  A set of bacterial strains for evaluation of beta-lactamase-stability of beta-lactam antibiotics.

Authors:  T Sawai; T Yoshida; K Tsukamoto; S Yamagishi
Journal:  J Antibiot (Tokyo)       Date:  1981-10       Impact factor: 2.649

3.  The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species.

Authors:  M H RIchmond
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

4.  Inhibition kinetics of three R-factor-mediated beta-lactamases by a new beta-lactam sulfone (CP 45899).

Authors:  R Labia; V Lelievre; J Peduzzi
Journal:  Biochim Biophys Acta       Date:  1980-02-14

5.  beta-Lactamase proceeds via an acyl-enzyme intermediate. Interaction of the Escherichia coli RTEM enzyme with cefoxitin.

Authors:  J Fisher; J G Belasco; S Khosla; J R Knowles
Journal:  Biochemistry       Date:  1980-06-24       Impact factor: 3.162

6.  Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid.

Authors:  J Fisher; R L Charnas; J R Knowles
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

7.  Inactivation of RTEM beta-lactamase from Escherichia coli by clavulanic acid and 9-deoxyclavulanic acid.

Authors:  R L Charnas; J R Knowles
Journal:  Biochemistry       Date:  1981-05-26       Impact factor: 3.162

8.  Inactivation of the RTEM beta-lactamase from Escherichia coli. Interaction of penam sulfones with enzyme.

Authors:  J Fisher; R L Charnas; S M Bradley; J R Knowles
Journal:  Biochemistry       Date:  1981-05-12       Impact factor: 3.162

9.  Inhibition of the RTEM beta-lactamase from Escherichia coli. Interaction of enzyme with derivatives of olivanic acid.

Authors:  R L Charnas; J R Knowles
Journal:  Biochemistry       Date:  1981-05-12       Impact factor: 3.162

10.  Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6 alpha- and 6 beta-monodeuterio and of 6,6-dideuterio derivatives with RTEM beta-lactamase from Escherichia coli.

Authors:  D G Brenner; J R Knowles
Journal:  Biochemistry       Date:  1981-06-23       Impact factor: 3.162

View more
  1 in total

Review 1.  In vitro and pharmacokinetic properties of the carbapenems.

Authors:  R Wise
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.